



Patent Application no. 09/972,402
Attorney's Docket No. 33053-034

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Kenneth C. Cundy. et al.

Application No.: 09/972,402

Filed: October 5, 2001

For: Compounds for Sustained Release of
Orally Delivered Drugs

)
)
) Group Art Unit: 1619

)
) Examiner: Unassigned

RECEIVED
FEB 01 2002
TECH CENTER 1600/2900
#5

**INFORMATION DISCLOSURE STATEMENT
TRANSMITTAL LETTER**

Assistant Commissioner for Patents
Washington, D.C. 20231


Sir:

Enclosed is an Information Disclosure Statement and accompanying form PTO-1449 for the above-identified patent application.

- ☒ No additional fee for submission of an IDS is required.
- ☐ The fee of IDS as set forth in 37 C.F.R. § 1.17(p) is also enclosed.
- ☐ A certification under 37 C.F.R. § 1.97(e) is also enclosed.
- ☐ A certification under 37 C.F.R. § 1.97(e), and the fee of IDS as set forth in 37 C.F.R. § 1.17(p) are also enclosed.
- ☐ Charge \$_____ to Deposit Account No. 02-4800 for the fee due.
- ☐ A check in the amount of \$_____ is enclosed for the fee due.

The Commissioner is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,
BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By: 
Anthony T. Cascio
Registration No. 29,904

P.O. Box 1404
Alexandria, Virginia 22313-1404
(650) 622-2300
Date: January 29, 2002



Patent Application no. 09/972,402
Attorney's Docket No. 033033-034

RECEIVED
FEB 01 2002
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Patent Application of)
Kenneth C. Cundy. et al.) Group Art Unit: 1619
Application No.: 09/972,402) Examiner: Unassigned
Filed: October 5, 2001)
For: Compounds for Sustained Release of)
Orally Delivered Drugs)

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, Applicants hereby submit the following information in conformance with 37 C.F.R. §§ 1.97 and 1.98. Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited below is enclosed:

Articles:

Gotoh, et al., *J. Pharmacol., Exp. Ther.*, 2000, 292, pp. 433-439
Iantomasi, et al., *Biochim. Biophys. Acta*, 1997, 1330, pp. 274-283
Kouzuki, et al., *J. Pharmacol. Exp. Ther.*, 1999, 288, pp. 627-634
Salach, et al., *Pharm. Res.*, 1994, 11, pp. 1429-1434
Suzuki, et al., *Sem. Liver Disease*, 2000, 20, pp. 251-263
Tokui, et al., *Pharm. Res.*, 1999, 16, pp. 904-908
Yamazaki, et al., *Drug Metab. Dispos.*, 1997, 15, pp. 1123-1129


FIELD(IDS DATE)

The documents are being submitted within 3 months of the filing or entry of the national stage of this application or before the first Office Action on the merits, whichever is later, therefore no fee or certification is required under 37 C.F.R. § 1.97(b).

To assist the Examiner, the documents are listed on the attached form PTO-1449. It is respectfully requested that an Examiner initialed copy of this form be returned to the undersigned.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By: 
Anthony T. Cascio
Registration No. 29,904

Burns, Doane, Swecker & Mathis
P.O. Box 1404
Arlington, VA 22313
Firm Phone: (650) 622-2300

Date: January 29, 2002